---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-059821"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T22:59:19.956970+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15

## Summary
- License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
- Agreement includes initial and annual fees from low to mid five figures, milestone payments, and royalties on net revenues.
- Silo submitted a pre-IND briefing package to FDA and plans 505(b)(2) pathway to shorten clinical timelines and reduce costs.
- Term runs per country/product until later of patent expiry, 20 years after first commercial sale, or end of market exclusivity.
- CEO Eric Weisblum states the license is a critical step that could increase shareholder value subject to FDA approval.

## SEC filing metadata
- accession: 0001213900-24-059821
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390024059821/0001213900-24-059821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390024059821/ea0209059-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-059821
- JSON: https://secwatch.observer/filing/0001213900-24-059821.json
- Plain text: https://secwatch.observer/filing/0001213900-24-059821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.